Cell Therapy News

Individuals with relapsed or refractory lymphoma who received chimeric antigen receptor T-cell therapy experienced a wide range of adverse events compared with those who received other treatments, study results showed.

The FDA has granted accelerated approval to a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma.

Use of subjective minimizing terminology, such as “safe” and “tolerable,” when discussing treatment-related toxicities occurs frequently at oncology and hematology conferences, according to a study published in Journal of Cancer Policy.

Allogeneic hematopoietic stem cell transplantation after CD19 chimeric antigen receptor T-cell therapy is thought to improve leukemia-free survival.

Chimeric antigen receptor T-cell therapy produced persistent, drug-free remission in patients with one of three different B-cell autoimmune diseases, researchers reported at ASH Annual Meeting and Exhibition.

The FDA has requested manufacturers of commercially available chimeric antigen receptor T-cell therapies now include a boxed safety warning regarding the risk for secondary T-cell malignancies on prescribing labels.

Results of a phase 1 trial for chimeric antigen receptor T cells targeting an orphan receptor in patients with relapsed or refractory multiple myeloma “thrilled” researchers, based on data presented at ASH Annual Meeting and Exhibition.

SAN DIEGO — The volume of hematopoietic stem cell transplantation procedures for advanced diffuse large B-cell lymphoma has declined precipitously since 2019, study results presented at ASH Annual Meeting and Exhibition showed.

Benefits of chimeric antigen receptor T-cell therapy far outweigh the risks involved, including secondary T-cell malignancies, according to Peter Marks, MD, PhD, director of the FDA’s Center for Biologic Evaluation and Research.

Researchers found lisocabtagene maraleucel to be a cost-effective second-line treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma, study findings published in Blood Advances showed.